ERAS 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-11

• On July 13, 2026, we announced updated preliminary Phase 1 data for ERAS-0015 in patients with RAS-mutant solid tumors from our ongoing AURORAS-1 Phase 1 trial in the United States that builds on our April 2026 announcement, with additional patients and longer follow-up.

• Encouraging Monotherapy Responses Observed in 2L+ KRAS G12X PDAC1

• Across doses, all patients with either confirmed or unconfirmed responses remained on treatment

• At RDE of 32 mg QD, 6 of 7 enrolled patients remained on treatment; at RDE of 24 mg QD, 6 of 8 enrolled patients remained on treatment

• With Additional Patients and Longer Follow-up, Monotherapy Safety Data Remained Consistent with Prior Disclosure and ERAS-0015 Continued to be Generally Well-Tolerated1

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• The following figure shows the RAS/MAPK pathway and how the three therapeutic strategies listed above attempt to comprehensively and synergistically shut down the RAS/MAPK pathway.

• In May 2025, in connection with our expectation that ERAS-0015 and ERAS-4001 would both become clinical stage programs, we conducted a broader pipeline review. Following this review, in order to prioritize organizational focus and resources to advance our differentiated RAS-targeting franchise, we d…

• Since our inception in 2018, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, identifying, acquiring, and in-licensing our product candidates, establishing our intellectual property portfolio, conducting research, preclini…

• We have incurred significant operating losses since inception. Our net losses were $183.4 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $1.1 billion. We expect our expenses and operating losses will …

• Based upon our current operating plans, we believe that our cash, cash equivalents, and marketable securities as of March 31, 2026 will be sufficient to fund our operations into the second half of 2028. We do not expect to generate any revenues from product sales until we successfully complete devel…

相对上期新增的文字 · 来源:10-Q · 2026-08-11

• On June 10, 2026, a purported securities class action complaint was filed against us and certain of our officers in the United States District Court for the Southern District of California. The complaint alleges violations of the federal securities laws and seeks damages, costs, and other unspecifie…

• In August 2026, a putative stockholder derivative complaint was filed in the United States District Court for the Southern District of California, captioned ES Trust v. Lim, et al., Case No. 3:26-cv-04517-WQH-JAC. The complaint named us as a nominal defendant and our current directors and Chief Fina…

• From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors,…

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• We are not currently a party to any material proceedings. From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and s…

相对上期新增的文字 · 来源:10-Q · 2026-08-11

• We are subject to securities class action litigation and a stockholder derivative complaint, and may become subject to additional litigation, which could result in substantial costs and divert management's attention.

• On June 10, 2026, a purported securities class action complaint was filed against us and certain of our officers in the United States District Court for the Southern District of California. The complaint alleges violations of the federal securities laws and seeks damages, costs, and other unspecifie…